Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
pharmaand GmbH
With
Gilead Sciences
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Solid tumor, advanced or metastatic, progressed on standard treatment participants in Arm B must have either triple negative breast cancer OR urothelial carcinoma OR ovarian cancer OR have a solid tumor with a deleterious mutation in BRCA1, BRCA2, PALB2, RAD51C or RAD51D
Measurable disease per RECIST v1.1
Adequate organ function
Eastern Cooperative Oncology Group (ECOG) 0 or 1
Tumor tissue for genomic analysis
Histologically or cytologically confirmed solid tumor, previously treated and measurable per RECIST v1.1, as follows:
Arm A: ovarian cancer with gBRCAwt disease, either platinum-sensitive OR platinum-resistant
Arm B: Metastatic triple negative breast cancer OR advanced/ metastatic urothelial carcinoma OR relapsed ovarian cancer
At least 1 prior line of standard therapy for advanced disease
Adequate organ function
ECOG 0 or 1
Tumor tissue for genomic analysis
You may not be if
Known history of myelodysplastic syndrome (MDS)
Symptomatic and/or untreated central nervous system (CNS) metastases
Prior poly (adenosine diphosphate \[ADP\]-ribose) polymerase (PARP) inhibitor treatment allowed for participants with ovarian cancer
Known history of MDS
Symptomatic and/or untreated CNS metastases
Clareo Health | A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)
